… ProQR Announces Fourth Quarter and Full Year 2019 Results and … & CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … 2020,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “In 2019 we shared positive Phase 1/2 data for …
… ProQR Announces Recent Progress and Financial Results for the … & CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, chief executive officer of ProQR. “In October we announced that LCA10 patients …
… ProQR to Present at Cowen and Company 40th Annual Health Care … will be accessible from the “Investors” section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… ProQR to Present at the Leerink Partners 4th Annual Rare … be accessible from the 'Investor Relations' section of ProQR's website ( www.proqr.com ) under 'Events and Presentations'. The …
… ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 … including sweat chloride, weight gain, change in CFQ-R Respiratory Symptom Score and FEV 1 , however, the study is … said Noreen R. Henig MD, Chief Medical Officer at ProQR. “We are grateful to the patients and the medical …